Immunogenicity and protective efficacy of a multi-antigenic adenovirus-based vaccine candidate against <i>Mycobacterium tuberculosis</i>.

ABSTRACT:

Introduction

The inadequate efficacy of the Bacillus Calmette-Guérin (BCG) vaccine against adult pulmonary tuberculosis (TB) necessitates the development of new and effective vaccines. Human adenovirus serotype 5 (Ad5), which induces T-cell response, is a widely used viral vector. In this study, we aimed to evaluate the efficacy of a multi-antigenic recombinant Ad5 vectored vaccine and determine the optimal immunization route for enhanced immune response against Mycobacterium tuberculosis.

Methods

We constructed a multi-antigenic recombinant Ad5 vectored vaccine expressing four antigens (Ag85B-ESAT6-MPT64-Rv2660c) of M. tuberculosis (rAd-TB4), immunized with rAd-TB4 (5 × 10⁷ infectious virus units/mouse) twice at an interval of 4 weeks starting at 10

SUBMITTER: Yun JS 

PROVIDER: S-EPMC11802578 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature